Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. Bardelli A, et al. Among authors: galimi f. Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2. Cancer Discov. 2013. PMID: 23729478 Free PMC article.
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. Bertotti A, et al. Among authors: galimi f. Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2. Cancer Discov. 2011. PMID: 22586653 Free article.
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.
Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, Lupo B, Erriquez J, Isella C, Comoglio PM, Medico E, Tejpar S, Budinská E, Trusolino L, Bertotti A. Zanella ER, et al. Among authors: galimi f. Sci Transl Med. 2015 Jan 28;7(272):272ra12. doi: 10.1126/scitranslmed.3010445. Sci Transl Med. 2015. PMID: 25632036 Free article.
HER2 activating mutations are targets for colorectal cancer treatment.
Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R. Kavuri SM, et al. Among authors: galimi f. Cancer Discov. 2015 Aug;5(8):832-41. doi: 10.1158/2159-8290.CD-14-1211. Cancer Discov. 2015. PMID: 26243863 Free PMC article.
Only a subset of Met-activated pathways are required to sustain oncogene addiction.
Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L. Bertotti A, et al. Among authors: galimi f. Sci Signal. 2009 Dec 8;2(100):ra80. doi: 10.1126/scisignal.2000643. Sci Signal. 2009. Corrected and republished in: Sci Signal. 2009;2(102):er11. doi: 10.1126/scisignal.2102er11 PMID: 19996456 Free article. Corrected and republished.
Only a subset of Met-activated pathways are required to sustain oncogene addiction.
Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L. Bertotti A, et al. Among authors: galimi f. Sci Signal. 2009;2(102):er11. doi: 10.1126/scisignal.2102er11. Sci Signal. 2009. PMID: 20039471
Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L. Bertotti A, et al. Among authors: galimi f. Clin Cancer Res. 2010 Aug 1;16(15):3933-43. doi: 10.1158/1078-0432.CCR-10-0106. Epub 2010 Jul 13. Clin Cancer Res. 2010. PMID: 20628031 Free article.
Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, Paraluppi G, Gonella F, Maione F, Pisacane A, David E, Torchio B, Risio M, Salizzoni M, Capussotti L, Perera T, Medico E, Di Renzo MF, Comoglio PM, Trusolino L, Bertotti A. Galimi F, et al. Clin Cancer Res. 2011 May 15;17(10):3146-56. doi: 10.1158/1078-0432.CCR-10-3377. Epub 2011 Mar 29. Clin Cancer Res. 2011. PMID: 21447729 Free article.
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A. Migliardi G, et al. Among authors: galimi f. Clin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683. Epub 2012 Mar 5. Clin Cancer Res. 2012. PMID: 22392911 Free article.
62 results